Skip to content
    Reviews

    Tandem ASCT Improves Event-Free Survival in High-Risk Neuroblastoma

    Park et alJournal of Clinical Medicine

    Tandem ASCT Improves Event-Free Survival in High-Risk Neuroblastoma
    In high-risk neuroblastoma, tandem high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is utilized to intensify consolidation therapy. While supported by one randomized trial, broader quantitative evidence has remained unexamined across synthesized cohorts. To address this, investigators searched PubMed, Embase, Web of Science, and Cochrane CENTRAL on 2 October 2026, systematically reviewing randomized and non-randomized studies comparing tandem versus single ASCT evaluating event-free survival (EFS) and overall survival (OS). Missing hazard ratios were derived from survival proportions and log-rank p-values. Study quality and certainty were evaluated using RoB 2, ROBINS-I, and GRADE methodologies.
    Across 698 screened records, five studies met inclusion criteria (one randomized trial and four non-randomized studies, encompassing 657 patients), with four studies (631 patients) eligible for quantitative pooling. In the randomized trial, tandem ASCT improved EFS (HR 0.67, 95% CI 0.49–0.92). Eligible non-randomized studies gave a similar estimate (HR 0.65, 95% CI 0.43–0.99), resulting in a pooled EFS HR of 0.66 (95% CI 0.51–0.85; I2 = 0%), representing about 13 additional event-free individuals per 100 at 3 years with moderate certainty.
    For overall survival, the pooled HR was 0.82 (95% CI 0.57–1.17) across two studies, carrying low certainty. EFS estimates ranged from 0.62 to 0.68 in sensitivity analyses but were attenuated (HR 0.82, 95% CI 0.56–1.19) after adding a registry that included relapsed and adult patients. The authors concluded that tandem ASCT probably improves EFS in high-risk neuroblastoma, whereas its effect on OS is uncertain, and noted that whether this benefit depends on anti-GD2 immunotherapy or persists against busulfan/melphalan regimens remains untested.

    Key Takeaways

    • Tandem autologous stem cell transplantation improved event-free survival compared with single transplantation, yielding a pooled hazard ratio of 0.66 (95% CI 0.51–0.85; I2 = 0%), corresponding to about 13 more event-free patients per 100 at 3 years.
    • Pooled analysis for overall survival showed a hazard ratio of 0.82 (95% CI 0.57–1.17) across two studies, reflecting low certainty of evidence.
    • Event-free survival estimates attenuated to a hazard ratio of 0.82 (95% CI 0.56–1.19) after adding registry data that included relapsed and adult patients.
    Read the original sourceJournal of Clinical Medicine